Last reviewed · How we verify
Cyclophosphamide-fludarabine-anti thymocyte globulin
Cyclophosphamide-fludarabine-anti thymocyte globulin is a Chemotherapy combination / Immunosuppressive conditioning regimen Small molecule drug developed by Cooperative Study Group A for Hematology. It is currently in Phase 3 development for Conditioning regimen for allogeneic hematopoietic stem cell transplantation in hematologic malignancies, Conditioning regimen for allogeneic hematopoietic stem cell transplantation in severe aplastic anemia. Also known as: CYCLOPHOSPHAMIDE,FLUDARA,ANTI-THYMOCYTE GLOBULINE.
This combination regimen uses cyclophosphamide and fludarabine to deplete immune cells, followed by anti-thymocyte globulin to further suppress T-cell mediated rejection, typically used as conditioning for hematopoietic stem cell transplantation.
This combination regimen uses cyclophosphamide and fludarabine to deplete immune cells, followed by anti-thymocyte globulin to further suppress T-cell mediated rejection, typically used as conditioning for hematopoietic stem cell transplantation. Used for Conditioning regimen for allogeneic hematopoietic stem cell transplantation in hematologic malignancies, Conditioning regimen for allogeneic hematopoietic stem cell transplantation in severe aplastic anemia.
At a glance
| Generic name | Cyclophosphamide-fludarabine-anti thymocyte globulin |
|---|---|
| Also known as | CYCLOPHOSPHAMIDE,FLUDARA,ANTI-THYMOCYTE GLOBULINE |
| Sponsor | Cooperative Study Group A for Hematology |
| Drug class | Chemotherapy combination / Immunosuppressive conditioning regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology / Hematology |
| Phase | Phase 3 |
Mechanism of action
Cyclophosphamide is an alkylating agent that causes DNA cross-linking and cell death across multiple cell types. Fludarabine is a purine analog that inhibits DNA synthesis and induces apoptosis in lymphocytes. Anti-thymocyte globulin (ATG) is a polyclonal antibody preparation that depletes T cells through complement-dependent and antibody-dependent cellular cytotoxicity. Together, this combination provides intensive immunosuppression and myeloablation suitable for conditioning prior to allogeneic hematopoietic stem cell transplantation.
Approved indications
- Conditioning regimen for allogeneic hematopoietic stem cell transplantation in hematologic malignancies
- Conditioning regimen for allogeneic hematopoietic stem cell transplantation in severe aplastic anemia
Common side effects
- Myelosuppression / neutropenia
- Infection
- Mucositis
- Hemorrhagic cystitis
- Nausea and vomiting
- Graft-versus-host disease (GVHD)
- Secondary malignancy
Key clinical trials
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (PHASE2)
- Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial (PHASE4)
- CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (PHASE1)
- TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (PHASE2)
- Stem Cell Transplantation in Crohn's Disease (PHASE1, PHASE2)
- A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) (PHASE3)
- Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia (PHASE2)
- Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclophosphamide-fludarabine-anti thymocyte globulin CI brief — competitive landscape report
- Cyclophosphamide-fludarabine-anti thymocyte globulin updates RSS · CI watch RSS
- Cooperative Study Group A for Hematology portfolio CI
Frequently asked questions about Cyclophosphamide-fludarabine-anti thymocyte globulin
What is Cyclophosphamide-fludarabine-anti thymocyte globulin?
How does Cyclophosphamide-fludarabine-anti thymocyte globulin work?
What is Cyclophosphamide-fludarabine-anti thymocyte globulin used for?
Who makes Cyclophosphamide-fludarabine-anti thymocyte globulin?
Is Cyclophosphamide-fludarabine-anti thymocyte globulin also known as anything else?
What drug class is Cyclophosphamide-fludarabine-anti thymocyte globulin in?
What development phase is Cyclophosphamide-fludarabine-anti thymocyte globulin in?
What are the side effects of Cyclophosphamide-fludarabine-anti thymocyte globulin?
Related
- Drug class: All Chemotherapy combination / Immunosuppressive conditioning regimen drugs
- Manufacturer: Cooperative Study Group A for Hematology — full pipeline
- Therapeutic area: All drugs in Oncology / Hematology
- Indication: Drugs for Conditioning regimen for allogeneic hematopoietic stem cell transplantation in hematologic malignancies
- Indication: Drugs for Conditioning regimen for allogeneic hematopoietic stem cell transplantation in severe aplastic anemia
- Also known as: CYCLOPHOSPHAMIDE,FLUDARA,ANTI-THYMOCYTE GLOBULINE
- Compare: Cyclophosphamide-fludarabine-anti thymocyte globulin vs similar drugs
- Pricing: Cyclophosphamide-fludarabine-anti thymocyte globulin cost, discount & access